首页 | 本学科首页   官方微博 | 高级检索  
检索        

米托蒽醌联合FLAG治疗复发性和难治性急性白血病的研究
引用本文:杨胜,徐景环,李尊昌.米托蒽醌联合FLAG治疗复发性和难治性急性白血病的研究[J].中国现代医生,2007,45(19):16-17.
作者姓名:杨胜  徐景环  李尊昌
作者单位:山东省滨州市人民医院血液科 山东滨州256610
摘    要:目的评价分析米托蒽醌联合FLAG方案治疗复发性和难治性急性白血病的临床疗效。方法米托蒽醌联合FLAG方案治疗20例难治性及复发性白血病。结果20例难治性及复发性白血病患者完全缓解率65%,部分缓解率10%,总有效率75%,主要不良反应为骨髓抑制。结论米托蒽醌联合FLAG方案是治疗难治性及复发性白血病的有效方法之一。

关 键 词:米托蒽醌  氟达拉滨  难治性  复发性白血病
文章编号:1673-9701(2007)19-16-03
修稿时间:2007年7月18日

Study of Mitoxantrone and FLAG Regimen in Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Authors:YANG Sheng XU Jinghuan LI Zunchang
Institution:YANG Sheng XU Jinghuan LI Zunchang Department of Hematology,Binzhou People's Hospital,Shangdong 256610
Abstract:Objective To evaluate the effect of fludarabine,Mitoxantrone and G-CSF regimen in treatment of refractory and relapsed acute myeloid leukemia.Methods 20 patients with refractory or relapsed acute myeloid leukemia(10 refractory AML patients,10 relapsed AML patients)were treated with the regimen.Results The rate of complete remission was 65%(13 /20),the rate of partial remission 10%(2/20),and the overall response rate 75.0%.Main toxicities were myelosupression and neutropenia,gastrointestinal side effects.Conclusion The regimen can be employed in treatment of the refractory or relapsed patients who were not responded to other regimen,and it is safe and effective.
Keywords:Mitoxantrone  Fludarabine  Refractory AML  Relapsed AML
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号